These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18982000)

  • 21. Expectations from cytotoxic chemotherapy.
    Tattersall MH
    Aust N Z J Surg; 1982 Aug; 52(4):335-40. PubMed ID: 6180722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis and cancer chemotherapy.
    Chresta CM; Arriola EL; Hickman JA
    Behring Inst Mitt; 1996 Oct; (97):232-40. PubMed ID: 8950479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcription factors and drug resistance.
    Kohno K; Uchiumi T; Niina I; Wakasugi T; Igarashi T; Momii Y; Yoshida T; Matsuo K; Miyamoto N; Izumi H
    Eur J Cancer; 2005 Nov; 41(16):2577-86. PubMed ID: 16209921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward a Better Understanding of the Complexity of Cancer Drug Resistance.
    Gottesman MM; Lavi O; Hall MD; Gillet JP
    Annu Rev Pharmacol Toxicol; 2016; 56():85-102. PubMed ID: 26514196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms.
    Reed JC
    Nat Clin Pract Oncol; 2006 Jul; 3(7):388-98. PubMed ID: 16826219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic therapy for solid tumors: from bench science to clinical trials.
    Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
    Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The TRAIL of oncogenes to apoptosis.
    Oikonomou E; Pintzas A
    Biofactors; 2013; 39(4):343-54. PubMed ID: 23813857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dual role of mutant p53 protein in chemosensitivity of human cancers.
    Mueller H; Eppenberger U
    Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy.
    McCarty MF; Block KI
    Integr Cancer Ther; 2006 Sep; 5(3):252-68. PubMed ID: 16880431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
    Koster R; van Vugt MA; Timmer-Bosscha H; Gietema JA; de Jong S
    Expert Rev Mol Med; 2013 Sep; 15():e12. PubMed ID: 24074238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
    Lefranc F; Facchini V; Kiss R
    Oncologist; 2007 Dec; 12(12):1395-403. PubMed ID: 18165616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update in cancer chemotherapy: genitourinary tract cancer, Part 4: Testicular cancer.
    Wright JC
    J Natl Med Assoc; 1988 Apr; 80(4):425-35. PubMed ID: 3290501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxygen delivery: implications for the biology and therapy of solid tumors.
    Rockwell S
    Oncol Res; 1997; 9(6-7):383-90. PubMed ID: 9406244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.